ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
November 08, 2021Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period.
Pharma Sources Insight January 2025
